Aduro Biotech has started dosing patients in a Phase Ib clinical trial of its drug candidate ADU-S100 (MIW815) in combination with Novartis’ PDR001 to treat advanced / metastatic solid tumours or lymphomas.

ADU-S100 is a synthetic, small molecule, immune modulator of STING pathway, while PDR001 is an investigational PD-1 checkpoint inhibitor.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The multi-centre, open-label dose escalation and dose expansion Phase Ib trial is designed to assess the safety and efficacy of the combination in around 175 subjects across the US, Europe, Canada, Australia and Japan.

Aduro Biotech chief medical officer Natalie Sacks said: “We are pleased with our early progress in the ongoing Phase I dose escalation trial of ADU-S100 as a single agent and are eager to expand our investigation into a separate clinical trial to evaluate the effect of ADU-S100 used in combination with the PDR001 checkpoint inhibitor.

“As a leader in STING activation, we look forward to gaining more insight into the potential therapeutic application of this novel combination therapy.”

The dose escalation part of the trial will include two treatment schedules, of which one group will be administered with fixed-dose intravenous PDR001 on day 1 and intratumoural ADU-S100 three times in a 28-day cycle.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“As a leader in STING activation, we look forward to gaining more insight into the potential therapeutic application of this novel combination therapy.”

Another group will be given fixed-dose intravenous PDR001 on day 1 and intratumoural ADU-S100 on day 1 of each 28-day cycle.

The expansion part of the trial will be initiated after determination of a maximum tolerated dose and / or recommended dose.

Aduro signed a collaboration and licence agreement with Novartis in 2015 to research, develop and commercialise immuno-oncology products using its STING pathway activator platform technology.

The firm is further studying safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumour activity of ADU-S100 in an ongoing multi-centre, dose escalation Phase I trial.

Image: Micrograph of Hodgkin lymphoma, a type of lymphoma. Photo: courtesy of Nephron via Wikimedia.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact